Retatrutide is going to make tirzepatide look quaint and people aren’t ready for the side effect conversation
Quick primer because this one’s coming fast. Semaglutide is GLP-1 only. Tirzepatide is GLP-1 plus GIP. Retatrutide is GLP-1 plus GIP plus glucagon. Triple agonist. The Phase 2 data showed something like 24% weight loss at 48 weeks, which is closer to bariatric surgery territory than traditional pharmacotherapy.
That’s the headline. Here’s the part nobody’s talking about yet.
The glucagon arm is what’s driving the additional weight loss beyond what tirz does, and glucagon agonism does a lot of things at once. It increases energy expenditure, which is great. It also affects hepatic glucose output and has real implications for people with any insulin resistance or fatty liver.
The trial data is encouraging on liver fat actually decreasing, but the long-term metabolic profile in a broader population is genuinely unknown.
Side effect profile in the trials was the usual GLP-1 stuff — nausea, GI issues, the same family of problems. Cardiovascular signals so far look fine but the trials aren’t big enough yet to call it.
The reta gray market is already huge. People are running it before there’s any real-world experience to draw on. We’re going to learn a lot about this molecule the hard way over the next two years.
If you’re going to use it anyway, the dosing people are converging on is much lower than what trials used — 2-4mg weekly versus 12mg in the trials — because the side effects at trial doses are rough.
Lower dose, slower titration, full bloodwork including lipids and liver enzymes, and treat it like the experimental drug it currently is.
This molecule is going to be huge. It’s also going to generate a lot of stories.